SHANGHAI, April 13,
2022 /PRNewswire/ -- On April, 2022, 111, Inc.
("111" or the "Company") (NASDAQ: YI), a leading tech-enabled
healthcare platform company in China, has set up an "Anti-Epidemic
Command" at the first opportunity to coordinate its relevant
departments and manpower to fully participate in the fight against
the pandemic in Shanghai. As a
provider of anti-epidemic items and drugs in Shanghai, 111 has so far opened various
supporting services, including antigen test product supplies, an
exclusive speedy procurement channel, chronic disease medication
registration, free online consultation, and prescription renewal
for chronic diseases. The company has already run direct transport
vehicles between its Kunshan-based East China Operation Center and
Shanghai, providing fast and
secure delivery of much-needed items and drugs in the fight against
the Covid-19 pandemic in Shanghai.
On April 7, the first batch of
anti-epidemic items and drugs were shipped to Shanghai from 111's East China Operation
Center in Kunshan, providing a timely boost for the ongoing fight
against the pandemic. The orders were collected and gathered
through an exclusive purchase channel of 111, and special personnel
were assigned to get them through the company's "Anti-Epidemic
Command", thus accelerating the order handling process and ensuring
the fastest delivery to the first line.
1 Pharmacy, 111's online drugstore, sells more than one hundred
thousand drugs online, covering more than 100 diseases. As medical
institutions and offline pharmacies struggle with supplies, 111's
digital healthcare platform can effectively make up for the
gap.
Targeting the problem of inconvenient drug purchases facing some
patients in Shanghai, 111 now
provides patients in need with "chronic disease medication
registration" and other services through doctors and pharmacists,
and readily assigns special personnel to follow up with any urgent
request for drugs. Every effort is being made to ease the "drug
supply shortage" arising from the current lockdown in Shanghai.
Since 1 Clinic, 111's online hospital, launched free clinic
services online, general practitioners and medical experts in
pediatrics, obstetrics and gynecology, internal medicine, surgery,
dermatology, oncology and other specialties have provided online
consultations, prescription renewal for chronic diseases, and other
services for the public. Electronic prescriptions have recently
increased by 20%, and convenient and professional medical services
are now made available to many people in need.
Dr. YU Gang, Co-founder & Executive Chairman of 111, stated,
"Shanghai is currently facing
tremendous challenges due to the Covid-19 pandemic. As a
Shanghai-based digital healthcare
company, we shoulder responsibilities to help the city overcome
various difficulties by fully leveraging our strengths in
integrated online/offline platform and smart supply chain. We will
devote every effort to support Shanghai to win this battle."
About 111, Inc.
111, Inc. (NASDAQ: YI) ("111" or the "Company") is a leading
tech-enabled healthcare platform company committed to digitally
connecting patients with medicine and healthcare services
in China. The Company provides consumers with better access to
pharmaceutical products and healthcare services directly through
its online retail pharmacy, 1 Pharmacy, and indirectly through its
offline virtual pharmacy network. The Company also offers online
healthcare services through its internet hospital, 1 Clinic, which
provides consumers with cost-effective and convenient online
consultation, electronic prescription service, and patient
management service. In addition, the Company's online platform, 1
Medicine, serves as a one-stop shop for pharmacies to source a vast
selection of pharmaceutical products. With the largest virtual
pharmacy network in China, 111 enables offline pharmacies to
better serve their customers with cloud-based services. 111 also
provides an omni-channel drug commercialization platform to its
strategic partners, which includes services such as digital
marketing, patient education, data analytics, and pricing
monitoring.
For more information on 111, please
visit: http://ir.111.com.cn/.
Forward-Looking Statements
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates," "target,"
"confident" and similar statements. Among other things, the
Business Outlook and quotations from management in this
announcement, as well as 111's strategic and operational plans,
contain forward-looking statements. 111 may also make written or
oral forward-looking statements in its periodic reports to the U.S.
Securities and Exchange Commission, in its annual report to
shareholders, in press releases and other written materials and in
oral statements made by its officers, directors or employees to
third parties. Such statements are based upon management's current
expectations and current market and operating conditions and relate
to events that involve known or unknown risks, uncertainties and
other factors, all of which are difficult to predict and many of
which are beyond the Company's control. Forward-looking statements
involve inherent risks, uncertainties and other factors that could
cause actual results to differ materially from those contained in
any such statements. Potential risks and uncertainties include, but
are not limited to, uncertainties as to the Company's ability
comply with extensive and evolving regulatory requirements, its
ability to compete effectively in the evolving PRC general health
and wellness market, its ability to manage the growth of its
business and expansion plans, its ability to achieve or maintain
profitability in the future, its ability to control the risks
associated with its pharmaceutical retail and wholesale businesses,
and the Company's ability to meet the standards necessary to
maintain listing of its ADSs on the Nasdaq Global Market, including
its ability to cure any non-compliance with Nasdaq's continued
listing criteria. Further information regarding these and other
risks, uncertainties or factors is included in the Company's
filings with the U.S. Securities and Exchange Commission. All
information provided in this press release is as of the date of
this press release, and 111 does not undertake any obligation to
update any forward-looking statement as a result of new
information, future events or otherwise, except as required under
applicable law.
SOURCE 111, Inc.
For further information: For further information: 111,
Inc., Investor Relations, Email: ir@111.com.cn; 111, Inc., Media
Relations, Email: press@111.com.cn, Phone: +86-021-2053 6666
(China)
View original
content:https://www.prnewswire.com/news-releases/111-inc-provides-urgently-needed-items-and-online-services-to-support-shanghais-fight-against-covid-19-pandemic-301524670.html
SOURCE 111, Inc.